---
title: "UCB SA (UCBJY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/UCBJY.US.md"
symbol: "UCBJY.US"
name: "UCB SA"
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:39:54.516Z"
locales:
  - [en](https://longbridge.com/en/quote/UCBJY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UCBJY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UCBJY.US.md)
---

# UCB SA (UCBJY.US)

## Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.ucb.com](https://www.ucb.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.30)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 34.74% |  |
| Net Profit YoY | 56.66% |  |
| P/B Ratio | 4.00 |  |
| Dividend Ratio | 0.64% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 51054917288.40 |  |
| Revenue | 8919300668.62 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.91% | A |
| Profit Margin | 20.13% | A |
| Gross Margin | 74.29% | A |
| Revenue YoY | 34.74% | A |
| Net Profit YoY | 56.66% | B |
| Total Assets YoY | 18.20% | A |
| Net Assets YoY | 22.36% | A |
| Cash Flow Margin | 147.05% | B |
| OCF YoY | 34.74% | A |
| Turnover | 0.44 | C |
| Gearing Ratio | 40.15% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - UCB SA",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "34.74%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "56.66%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.64%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "51054917288.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8919300668.62",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.91%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "20.13%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "74.29%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "34.74%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "56.66%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.20%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "22.36%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "147.05%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "34.74%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.15%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.44 | 46/190 | 37.31 | 32.95 | 30.13 |
| PB | 4.00 | 136/190 | 4.84 | 4.34 | 3.69 |
| PS (TTM) | 5.72 | 102/190 | 7.26 | 6.26 | 5.71 |
| Dividend Yield | 0.64% | 30/190 | 0.72% | 0.60% | 0.55% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-05T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 136.00 |
| Highest Target | 164.04 |
| Lowest Target | 161.96 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/UCBJY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/UCBJY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/UCBJY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/UCBJY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**